Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
Clinical trial NCT05038813 · UNKNOWN
Trial details
- NCT number
- NCT05038813
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-14
- Primary completion
- 2024-03-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.